Imugene Ltd
ASX:IMU

Watchlist Manager
Imugene Ltd Logo
Imugene Ltd
ASX:IMU
Watchlist
Price: 0.345 AUD -1.43% Market Closed
Market Cap: 108.8m AUD
Section:
 

Relative Value

There is not enough data to reliably calculate the relative value of IMU.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMU Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
Forward
43.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-28.3
Industry
23.5
Forward
-0.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6.5
Median 5Y
-34.1
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-33.9
Industry
24.3
More Details
2.4
P/B
P/B
Price to Book Value
2.4
vs History
90
vs Industry
24
Median 3Y
5
Median 5Y
6.3
Industry
3.2
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
Forward
34.7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-23.3
Industry
5.9
Forward
-2.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-23.3
Industry
6.2
Forward
-0.9
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-29.7
Industry
7.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-29.5
Industry
6.3
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
92
vs Industry
39
Median 3Y
8.7
Median 5Y
22.1
Industry
5.6
More Details

Multiples Across Competitors

IMU Competitors Multiples
Imugene Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Imugene Ltd
ASX:IMU
108.8m AUD 0 -1.6 -1.1 -1.1
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 254 975 585.5 -17 510 082.5 -17 182 753 -17 144 504.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 968 621.2 -161 447.8 -196 049.2 -193 812
US
Abbvie Inc
NYSE:ABBV
412.5B USD 6.9 175.7 16.9 24
US
Amgen Inc
NASDAQ:AMGN
183.8B USD 5.1 26.2 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123B USD 10.5 33.5 24.6 25.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 073.9 -529.2 -576.3 -560.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
85.5B USD 6 18.7 17.9 20.3
AU
CSL Ltd
ASX:CSL
84.5B AUD 3.6 18.9 12.8 15.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
55.7B USD 17.3 1 278.1 172.4 209.1
P/S Multiple
Revenue Growth P/S to Growth
AU
Imugene Ltd
ASX:IMU
Average P/S: 28 894 633.5
Not Available 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
254 975 585.5
140%
1 821 254.2
FR
Pharnext SCA
OTC:PNEXF
33 968 621.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.9
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.5
10%
1
US
E
Epizyme Inc
F:EPE
2 073.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
6
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.3
46%
0.4
P/E Multiple
Earnings Growth PEG
AU
Imugene Ltd
ASX:IMU
Average P/E: 224.3
Negative Multiple: -1.6 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 510 082.5 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 447.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
175.7
89%
2
US
Amgen Inc
NASDAQ:AMGN
26.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
33.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
10%
1.9
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 278.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Imugene Ltd
ASX:IMU
Average EV/EBITDA: 39.5
Negative Multiple: -1.1 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 182 753 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 049.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.9
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
11%
1.6
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
172.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Imugene Ltd
ASX:IMU
Average EV/EBIT: 46.7
Negative Multiple: -1.1 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 144 504.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 812 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.7
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20.3
13%
1.6
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
209.1
N/A N/A

See Also

Summary
IMU intrinsic value, competitors valuation, and company profile.
DCF Valuation
IMU stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IMU stock valuation using valuation multiples.
Wall Street Estimates
IMU price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IMU stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.